HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Jan.26) - Key Takeaways from the Failure of Henlius Privatization, TCM M&As

China Healthcare Weekly (Feb.2)- Update on CR Sanjiu's Acquisition of Tasly, China Biotech's Outlook

China Healthcare Weekly (Feb.9) - Vesync Is a High-Quality Company, VBP to Cover Retail Pharmacies

China TCM (570.HK) - About the Profit Warning and the Valuation Outlook

Shanghai Henlius Biotech (2696 HK)- These Are the Reasons Why LVC May Vote Against the Privatization

Shanghai Henlius Biotech Privatization (2696.HK) - The Offer Price Is Disappointing

Shanghai Henlius Biotech (2696 HK) - Some Thoughts About the Privatization

Equity Bottom-Up

Shanghai Henlius Biotech  / Equity Bottom-Up

<ul>
<li>Lin Lijun voted against the privatization, which is in line with our analysis.Lin and some other long-term investors expressed their "dissatisfaction" by opposing the privatization due to disappointing Cancellation Price.</li>
<li>Due to deal break, Henlius’ share price could be under pressure in short term.Investors may need to wait until the implementation of biosimilar VBP in 2025 to see situation clearly.</li>
<li>Despite biosimilar VBP, we remain optimistic about the outlook of Henlius, because its future development positioning will not be limited to just biosimilars, but will focus on internationalization.</li>
</ul>


Lin Lijun voted against the privatization, which is in line with our analysis.Lin and some other long-term investors expressed their "dissatisfaction" by opposing the privatization due to disappointing Cancellation Price.
Due to deal break, Henlius’ share price could be under pressure in short term.Investors may need to wait until the implementation of biosimilar VBP in 2025 to see situation clearly.
Despite biosimilar VBP, we remain optimistic about the outlook of Henlius, because its future development positioning will not be limited to just biosimilars, but will focus on internationalization.


Shanghai Henlius Biotech (2696 HK) - About the Deal Break and the Valuation Outlook